Multiplex screen of serum biomarkers in facioscapulohumeral muscular dystrophy

Journal of Neuromuscular Diseases

Volumn 1, Issue 2, 2014, Pages 181-190

  Statland, Jeffrey ^a,b   Donlin Smith, Colleen M ^b   Tapscott, Stephen J ^c   Van Der Maarel, Silvère M ^d   Tawil, Rabi ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c USA   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; DUX4; Facioscapulohumeral muscular dystrophy; Muscle Disease; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CA 15-3 ANTIGEN; CALGRANULIN C; CCL23 CHEMOKINE; CD40 LIGAND; CHEMOKINE; COMPLEMENT COMPONENT C3; CREATINE KINASE MB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LEPTIN; MESOTHELIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOGLOBIN; PHOSPHOSERINE; PHOSPHOSERINE AMINOTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN BINDING PROTEIN 1; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG; VITRONECTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; MALE; MIDDLE AGED; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; YOUNG ADULT;

EID: 84948131848     PISSN: 22143599     EISSN: 22143602     Source Type: Journal    
DOI: 10.3233/JND-140034     Document Type: Article

References (31)

1. Flanigan, K. M., Coffeen, C. M., Sexton, L., Stauffer, D., Brunner, S., Leppert, M. F. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord. 2001; 11: 525-529.
2. Mostacciuolo, M. L., Pastorello, E., Vazza, G., et al. Facioscapulohumeral muscular dystrophy: Epidemiological and molecular study in a north-east Italian population sample. Clin Genet. 2009; 75: 550-555.
3. Norwood, F. L., Harling, C., Chinnery, P. F., Eagle, M., Bushby, K., Straub, V. Prevalence of genetic muscle disease in Northern England: In-depth analysis of a muscle clinic population. Brain. 2009; 132: 3175-3186.
4. Padberg, G. W., Frants, R. R., Brouwer, O. F., Wijmenga, C., Bakker, E., Sandkuijl, L. A. Facioscapulohumeral muscular dystrophy in the Dutch population. Muscle Nerve. 1995; 2: S81-S84.
5. Tawil, R., van der Maarel, S., Padberg, G. W., van Enge-len, B. G. 171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2010; 20: 471-475.
6. van der Maarel, S. M., Tawil, R., Tapscott, S. J. Facioscapulohumeral muscular dystrophy and DUX4: Breaking the silence. Trends Mol Med. 2011; 17: 252-258.
7. Lemmers, R. J., van der Vliet, P. J., Klooster, R., et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science. 2010; 329: 1650-1653.
8. Tawil, R., Shaw, D. W., van der Maarel, S. M., Tapscott, S. J. Clinical trial preparedness in facioscapulohumeral dystrophy: Outcome measures and patient access: 8-9 April 2013, Leiden, The Netherlands. Neuromuscul Disord. 2014; 24: 79-85.
9. Geng, L. N., Yao, Z., Snider, L., et al. DUX4 activates germline genes, retroelements, and immune mediators: Implications for facioscapulohumeral dystrophy. Dev Cell. 2012; 22: 38-51.
10. Arahata, K., Ishihara, T., Fukunaga, H., et al. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): Immunocytochemical and genetic analyses. Muscle Nerve. 1995; 2: S56-S66.
11. Frisullo, G., Frusciante, R., Nociti, V., et al. CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol. 2011; 31: 155-166.
12. Tasca, G., Pescatori, M., Monforte, M., et al. Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS One. 2012; 7: e38779.
13. Osborne, R. J., Welle, S., Venance, S. L., Thornton, C. A., Tawil, R. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology. 2007; 68: 569-577.
14. Rahimov, F., King, O. D., Leung, D. G., et al. Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers. Proc Natl Acad Sci U S A. 2012; 109: 16234-16239.
15. Winokur, S. T., Chen, Y. W., Masny, P. S., et al. Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet. 2003; 12: 2895-2907.
16. de Greef, J. C., Lemmers, R. J., Camano, P., et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology. 2010; 75: 1548-1554.
17. Orrell, R. W., Tawil, R., Forrester, J., Kissel, J. T., Mendell, J. R., Figlewicz, D. A. Definitive molecular diagnosis of facioscapulohumeral dystrophy. Neurology. 1999; 52: 1822-1826.
18. Lemmers, R. J., Tawil, R., Petek, L. M., et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet. 2012; 44: 1370-1374.
19. Ricci,E.,Galluzzi,G.,Deidda,G.,etal.Progressinthemolec-ular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol. 1999; 45: 751-757.
20. Chowdhury, F., Williams, A., Johnson, P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods. 2009; 340: 55-64.
21. Krishhan, V. V., Khan, I. H., Luciw, P. A. Multiplexed microbead immunoassays by flow cytometry for molecular profiling: Basic concepts and proteomics applications. Crit Rev Biotechnol. 2009; 29: 29-43.
22. Benjamini, Y., Hochberg, Y. Controlling the false discovery rate: A practical and pwerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological). 1995; 57: 289-300.
23. Pike, N. Using false discovery rates for multiple comparisons in ecology and evolution. Ecology and Evolution. 2011; 2: 278-282.
24. Snider, L., Geng, L. N., Lemmers, R. J., et al. Facioscapulohumeral dystrophy: Incomplete suppression of a retrotrans-posed gene. PLoS Genet. 2010; 6: e1001181.
25. Carpenter, S. K. G. Pathology of Skeletal Muscle. Second Edition ed. 2001, New York: Oxford University Press.
26. De Paepe, B., Creus, K. K., Martin, J. J., De Bleecker, J. L. Upregulation of chemokines and their receptors in Duchenne muscular dystrophy: Potential for attenuation of myofiber necrosis. Muscle Nerve. 2012; 46: 917-925.
27. Porter, J. D., Guo, W., Merriam, A. P., et al. Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscul Disord. 2003; 13: 223-235.
28. Diaz-Ramos, A., Roig-Borrellas, A., Garcia-Melero, A., Llorens, A., Lopez-Alemany, R. Requirement of plasminogen binding to its cell-surface receptor alpha-enolase for efficient regeneration of normal and dystrophic skeletal muscle. PLoS One. 2012; 7: e50477.
29. Lopez-Alemany, R., Suelves, M., Munoz-Canoves, P. Plasmin generation dependent on alpha-enolase-type plasminogen receptor is required for myogenesis. Thromb Haemost. 2003; 90: 724-733.
30. Johansson, A., Boman, K., Cederquist, K., Forsberg, H., Ols-son, T. Increased levels of tPA antigen and tPA/PAI-1 complex in myotonic dystrophy. J Intern Med. 2001; 249: 503-510.
31. Gomez, J. M., Molina, A., Fernandez-Castaner, M., Casamit-jana, R., Martinez-Matos, J. A., Soler, J. Insulin regulation of leptin synthesis and secretion in humans: The model of myotonic dystrophy. Clin Endocrinol (Oxf). 1999; 50: 569-575.